Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ejaculation-sparing enucleation of the prostate with Thulium: Yag laser (ES-ThuLEP) versus Thulium Fiber laser (ES-ThuFLEP): outcomes on sexual function.
World J Urol
January 2025
Department of Urology, Azienda Socio Sanitaria Territoriale Lariana, Como, Italy.
Purpose: To compare the effect on sexual function of ejaculation-sparing enucleation of the prostate using Thulium: YAG laser (ES-ThuLEP) versus continuous-wave Thulium Fiber Laser (ES-ThuFLEP).
Methods: 112 patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia who wished to preserve ejaculation were treated. 58 patients underwent ES-ThuLEP (Group A) using the Cyber TM generator.
Associations between serum total bilirubin and overactive bladder from the National Health and Nutrition Examination Survey.
Front Endocrinol (Lausanne)
January 2025
Department of Urology, Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng, Jiangsu, China.
Background: The relationship between serum total bilirubin (STB) concentrations and the risk of overactive bladder (OAB) remains uncertain. This study aims to explore the potential connection between STB and OAB.
Method: We utilized data from the National Health and Nutrition Examination Survey (NHANES) database for the years 2001-2020.
Prostate Artery Embolization in the Setting of Prostate Cancer: Review and Opinion.
Cancer Control
January 2025
Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Prostate Artery Embolization (PAE) is a novel minimally invasive angiographic technique that has been used effectively to treat men with lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH). However, applications of PAE for men with prostate cancer have been minimally studied. This review serves as an update on the status of PAE in men with prostate cancer, as well as a discussion of emerging indications.
View Article and Find Full Text PDFComparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis.
BMC Urol
January 2025
Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
Background: Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes.
View Article and Find Full Text PDFDecreased nitric oxide production is a novel therapeutic target for salt-induced nocturnal polyuria in aging.
Sci Rep
January 2025
Department of Urology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita-city, 565-0871, Osaka, Japan.
Nocturnal polyuria is a major cause of nocturia, which affects quality of life. Aging-related decreases in nitric oxide production have been reported to contribute to salt-induced nocturnal polyuria. We posited that enhanced nitric oxide production from exercise could mitigate salt-induced nocturnal polyuria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!